{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:12:47Z","timestamp":1788534767239,"version":"build-2803163510"},"reference-count":206,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1124\/pharmrev.120.000160","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T16:15:43Z","timestamp":1625069743000},"page":"1001-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["New Aspects of Diabetes Research and Therapeutic Development"],"prefix":"10.1016","volume":"73","author":[{"given":"Leslie S.","family":"Satin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Soleimanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.120.000160_bib1","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132594","article-title":"Pharmacologic and genetic approaches define human pancreatic \u03b2 cell mitogenic targets of DYRK1A inhibitors","volume":"5","author":"Ackeifi","year":"2020","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000160_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/meta.2000.7729","article-title":"T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats","volume":"49","author":"Adachi","year":"2000","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.120.000160_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11892-020-01309-9","article-title":"Gastrointestinal peptides as therapeutic targets to mitigate obesity and metabolic syndrome","volume":"20","author":"Alexiadou","year":"2020","journal-title":"Curr Diab Rep"},{"key":"10.1124\/pharmrev.120.000160_bib4","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0079-6107(89)90013-8","article-title":"Electrophysiology of the pancreatic beta-cell","volume":"54","author":"Ashcroft","year":"1989","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1124\/pharmrev.120.000160_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/bst0180109","article-title":"ATP-sensitive K+ channels: a link between B-cell metabolism and insulin secretion","volume":"18","author":"Ashcroft","year":"1990","journal-title":"Biochem Soc Trans"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.120.000160_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dom.12716","article-title":"\u03b2-Cell adaptation in pregnancy","volume":"18","author":"Baeyens","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2337\/diacare.15.6.755","article-title":"Biguanides and NIDDM","volume":"15","author":"Bailey","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib9","doi-asserted-by":"crossref","first-page":"eaam7543","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000160_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/db13-1146","article-title":"Human \u03b2-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map","volume":"63","author":"Bernal-Mizrachi","year":"2014","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/pharmrev.120.000160_bib13","first-page":"554","article-title":"Banting\u2019s, Best\u2019s, and Collip\u2019s accounts of the discovery of insulin","volume":"56","author":"Bliss","year":"1982","journal-title":"Bull Hist Med"},{"key":"10.1124\/pharmrev.120.000160_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41551-018-0275-1","article-title":"Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques","volume":"2","author":"Bochenek","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1124\/pharmrev.120.000160_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000160_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1185\/03007998409109558","article-title":"Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects","volume":"9","author":"Bonora","year":"1984","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.120.000160_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJM198508083130604","article-title":"In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis","volume":"313","author":"Bottazzo","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1478-7954-8-29","article-title":"Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence","volume":"8","author":"Boyle","year":"2010","journal-title":"Popul Health Metr"},{"key":"10.1124\/pharmrev.120.000160_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nm1546","article-title":"Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment","volume":"13","author":"Brunham","year":"2007","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000160_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib21","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126742","article-title":"\u03b2 Cell tone is defined by proglucagon peptides through cAMP signaling","volume":"4","author":"Capozzi","year":"2019","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000160_bib23","article-title":"Glucagon lowers glycemia when \u03b2-cells are active","volume":"5","author":"Capozzi","year":"2019","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000160_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.molmet.2017.04.002","article-title":"Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human \u03b2-cell survival and proliferation","volume":"6","author":"Carboneau","year":"2017","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib25","doi-asserted-by":"crossref","first-page":"101071","DOI":"10.1016\/j.molmet.2020.101071","article-title":"SGLT2 is not expressed in pancreatic \u03b1- and \u03b2-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans","volume":"42","author":"Chae","year":"2020","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib26","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1172\/JCI69004","article-title":"Menin determines K-RAS proliferative outputs in endocrine cells","volume":"124","author":"Chamberlain","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature10502","article-title":"PDGF signalling controls age-dependent proliferation in pancreatic \u03b2-cells","volume":"478","author":"Chen","year":"2011","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib28","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.2337\/db15-0083","article-title":"Augmented Stat5 signaling bypasses multiple impediments to lactogen-mediated proliferation in human \u03b2-cells","volume":"64","author":"Chen","year":"2015","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib29","doi-asserted-by":"crossref","first-page":"E1133","DOI":"10.1152\/ajpendo.90944.2008","article-title":"Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein","volume":"296","author":"Chen","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib30","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1096\/fj.08-111690","article-title":"Thioredoxin-interacting protein deficiency induces Akt\/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes","volume":"22","author":"Chen","year":"2008","journal-title":"FASEB J"},{"key":"10.1124\/pharmrev.120.000160_bib31","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2337\/db07-0715","article-title":"Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis","volume":"57","author":"Chen","year":"2008","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib32","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1073\/pnas.1424684112","article-title":"Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates","volume":"112","author":"Chou","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000160_bib33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.molmet.2017.06.001","article-title":"Endoplasmic reticulum stress and eIF2\u03b1 phosphorylation: the Achilles heel of pancreatic \u03b2 cells","volume":"6","author":"Cnop","year":"2017","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib34","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1210\/jc.2003-030421","article-title":"Oxyntomodulin suppresses appetite and reduces food intake in humans","volume":"88","author":"Cohen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","article-title":"PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-\u03b1 and-\u03b3 via IRF1 induction","volume":"36","author":"Colli","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1124\/pharmrev.120.000160_bib37","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.2337\/dc19-0556","article-title":"Lack of durable improvements in \u03b2-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib38","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1172\/JCI91761","article-title":"Age-dependent human \u03b2 cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling","volume":"127","author":"Dai","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib39","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI83657","article-title":"Stress-impaired transcription factor expression and insulin secretion in transplanted human islets","volume":"126","author":"Dai","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib40","doi-asserted-by":"crossref","first-page":"bqaa080","DOI":"10.1210\/endocr\/bqaa080","article-title":"Dapagliflozin does not directly affect human \u03b1 or \u03b2 cells","volume":"161","author":"Dai","year":"2020","journal-title":"Endocrinology"},{"key":"10.1124\/pharmrev.120.000160_bib41","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1210\/endo.142.10.8430","article-title":"Oxyntomodulin inhibits food intake in the rat","volume":"142","author":"Dakin","year":"2001","journal-title":"Endocrinology"},{"key":"10.1124\/pharmrev.120.000160_bib42","doi-asserted-by":"crossref","first-page":"E1173","DOI":"10.1152\/ajpendo.00233.2002","article-title":"Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats","volume":"283","author":"Dakin","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib43","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.2337\/db13-0265","article-title":"Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates","volume":"62","author":"Defronzo","year":"2013","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib44","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI119743","article-title":"Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids","volume":"100","author":"Delaunay","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrd.2016.232","article-title":"Advances in islet encapsulation technologies","volume":"16","author":"Desai","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.120.000160_bib46","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1373\/clinchem.2016.256842","article-title":"Metformin and the gut microbiome in diabetes","volume":"62","author":"Devaraj","year":"2016","journal-title":"Clin Chem"},{"key":"10.1124\/pharmrev.120.000160_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmat4866","article-title":"Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates","volume":"16","author":"Doloff","year":"2017","journal-title":"Nat Mater"},{"key":"10.1124\/pharmrev.120.000160_bib48","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-019-0213-9","article-title":"Targeting innate immune mediators in type 1 and type 2 diabetes","volume":"19","author":"Donath","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/pharmrev.120.000160_bib49","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.120.000160_bib50","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.120.000160_bib51","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000160_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI88877","article-title":"Islet inflammation in type 2 diabetes and physiology","volume":"127","author":"Eguchi","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib53","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gt.2015.18","article-title":"\u03b2-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection","volume":"22","author":"El Khatib","year":"2015","journal-title":"Gene Ther"},{"key":"10.1124\/pharmrev.120.000160_bib54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(16)32567-3","article-title":"Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial","volume":"389","author":"El-Khatib","year":"2017","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12031-007-9002-1","article-title":"Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons","volume":"34","author":"El-Mir","year":"2008","journal-title":"J Mol Neurosci"},{"key":"10.1124\/pharmrev.120.000160_bib56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I","volume":"275","author":"El-Mir","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000160_bib57","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma Insulin Response to Oral and Intravenous Glucose Administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib58","doi-asserted-by":"crossref","first-page":"211ra156","DOI":"10.1126\/scitranslmed.3006534","article-title":"Restoration of the unfolded protein response in pancreatic \u03b2 cells protects mice against type 1 diabetes [published correction appears in Sci Transl Med (2013) 5:214er11]","volume":"5","author":"Engin","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1124\/pharmrev.120.000160_bib59","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1124\/pharmrev.120.000160_bib60","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1128\/MCB.01179-08","article-title":"Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure","volume":"29","author":"Evans-Molina","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1124\/pharmrev.120.000160_bib61","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1210\/jc.2007-1212","article-title":"Salicylates increase insulin secretion in healthy obese subjects","volume":"93","author":"Fern\u00e1ndez-Real","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib62","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.120.000160_bib63","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/pharmrev.120.000160_bib64","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Foretz","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib65","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.120.000160_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib67","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib68","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000160_bib69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1210\/jcem-61-1-160","article-title":"Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus","volume":"61","author":"Giugliano","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/08830180500379721","article-title":"Immunotherapy for the prevention and treatment of type 1 diabetes","volume":"24","author":"Goudy","year":"2005","journal-title":"Int Rev Immunol"},{"key":"10.1124\/pharmrev.120.000160_bib72","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1210\/jc.2012-1206","article-title":"Formation of a human \u03b2-cell population within pancreatic islets is set early in life","volume":"97","author":"Gregg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib74","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2337\/dci16-0008","article-title":"Islet transplantation for hypoglycemia unawareness\/severe hypoglycemia: caveat emptor","volume":"39","author":"Harlan","year":"2016","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.120.000160_bib75","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/0168-8227(91)90010-B","article-title":"Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM","volume":"14","author":"Harrower","year":"1991","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/pharmrev.120.000160_bib76","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","article-title":"Metformin action: concentrations matter","volume":"21","author":"He","year":"2015","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.120.000160_bib77","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1080\/14656566.2019.1672660","article-title":"Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes","volume":"20","author":"Hedrington","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.120.000160_bib78","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/dc15-1988","article-title":"Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia","volume":"39","author":"Hering","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib79","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jama.293.7.830","article-title":"Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes","volume":"293","author":"Hering","year":"2005","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000160_bib80","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib81","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMp1309610","article-title":"The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience","volume":"369","author":"Hiatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.TP.0000068899.48252.1D","article-title":"Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model","volume":"76","author":"Hirshberg","year":"2003","journal-title":"Transplantation"},{"key":"10.1124\/pharmrev.120.000160_bib83","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2018.11.018","article-title":"Patient adipose stem cell-derived adipocytes reveal genetic variation that predicts antidiabetic drug response","volume":"24","author":"Hu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1124\/pharmrev.120.000160_bib84","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib85","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.bmc.2012.03.051","article-title":"Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus","volume":"20","author":"Imamura","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/pharmrev.120.000160_bib86","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib87","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/db10-1392","article-title":"Effects of rosiglitazone, glyburide, and metformin on \u03b2-cell function and insulin sensitivity in ADOPT","volume":"60","author":"Kahn","year":"2011","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib88","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2337\/db10-0308","article-title":"Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women","volume":"59","author":"Kars","year":"2010","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib89","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/244447a0","article-title":"Transplantation of isolated pancreatic islets into the portal vein of diabetic rats","volume":"244","author":"Kemp","year":"1973","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib90","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2337\/diabetes.51.3.676","article-title":"Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells","volume":"51","author":"Kim","year":"2002","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib91","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2337\/diabetes.49.9.1517","article-title":"Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter","volume":"49","author":"Kim","year":"2000","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib92","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2337\/dc13-2977","article-title":"Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study","volume":"37","author":"Kim","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib93","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.diabres.2017.07.015","article-title":"Metformin treatment significantly enhances intestinal glucose uptake in patients with type 2 diabetes: Results from a randomized clinical trial","volume":"131","author":"Koffert","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/pharmrev.120.000160_bib94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cmet.2020.07.012","article-title":"Microbial imidazole propionate affects responses to metformin through p38\u03b3-dependent inhibitory AMPK phosphorylation","volume":"32","author":"Koh","year":"2020","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.120.000160_bib95","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib96","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00125-019-4849-6","article-title":"No direct effect of SGLT2 activity on glucagon secretion","volume":"62","author":"Kuhre","year":"2019","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib97","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2337\/db12-0018","article-title":"Human \u03b2-cell proliferation and intracellular signaling: driving in the dark without a road map","volume":"61","author":"Kulkarni","year":"2012","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.120.000160_bib99","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","article-title":"Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use","volume":"49","author":"Kurtzhals","year":"2000","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib100","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.bcp.2008.07.029","article-title":"DPP4 inhibitors for diabetes--what next?","volume":"76","author":"Lambeir","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.120.000160_bib101","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s00125-006-0590-z","article-title":"Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes","volume":"50","author":"Laybutt","year":"2007","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1124\/pharmrev.120.000160_bib103","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.120.000160_bib104","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"10.1124\/pharmrev.120.000160_bib105","first-page":"421","article-title":"Pharmacological regulation of hepatic glucose production","volume":"4","author":"Link","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/pharmrev.120.000160_bib106","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"Luippold","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib107","doi-asserted-by":"crossref","first-page":"22524","DOI":"10.1074\/jbc.M116.741694","article-title":"Peroxisome proliferator-activated receptor-\u03b3 activation augments the \u03b2-cell unfolded protein response and rescues early glycemic deterioration and \u03b2 cell death in non-obese diabetic mice","volume":"291","author":"Maganti","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000160_bib108","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/ijerph16152720","article-title":"The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect","volume":"16","author":"Makrilakis","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1124\/pharmrev.120.000160_bib109","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s00125-007-0816-8","article-title":"The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients","volume":"50","author":"Marchetti","year":"2007","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib110","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00125-012-2604-3","article-title":"Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes","volume":"55","author":"Marhfour","year":"2012","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib111","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib112","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2967\/jnumed.112.106666","article-title":"Metformin temporal and localized effects on gut glucose metabolism assessed using 18F-FDG PET in mice","volume":"54","author":"Massollo","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1124\/pharmrev.120.000160_bib114","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance","volume":"2","author":"McIntyre","year":"1964","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib116","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib117","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.2337\/db07-1369","article-title":"Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans","volume":"57","author":"Meier","year":"2008","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib118","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.120.000160_bib119","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11781","article-title":"How insulin engages its primary binding site on the insulin receptor","volume":"493","author":"Menting","year":"2013","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib121","first-page":"90","article-title":"Weitere Mitteilungen \u00fcber den Diabetes mellitus nach Extirpation des Pankreas","volume":"29","author":"Minkowski","year":"1892","journal-title":"Berliner Klinische Wochenschrift"},{"key":"10.1124\/pharmrev.120.000160_bib122","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2337\/diacare.27.7.1791","article-title":"The phantom of lactic acidosis due to metformin in patients with diabetes","volume":"27","author":"Misbin","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib123","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.2337\/dc12-0508","article-title":"Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes","volume":"35","author":"Mudaliar","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib124","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1210\/en.2011-1485","article-title":"Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell","volume":"152","author":"Mulherin","year":"2011","journal-title":"Endocrinology"},{"key":"10.1124\/pharmrev.120.000160_bib125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib126","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/14656566.2017.1323878","article-title":"Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?","volume":"18","author":"Munir","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.120.000160_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0010058","article-title":"Pancreatic islet transplantation","volume":"1","author":"Naftanel","year":"2004","journal-title":"PLoS Med"},{"key":"10.1124\/pharmrev.120.000160_bib128","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib129","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nature06406","article-title":"Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A","volume":"450","author":"Nejentsev","year":"2007","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib131","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature04711","article-title":"KATP channels as molecular sensors of cellular metabolism","volume":"440","author":"Nichols","year":"2006","journal-title":"Nature"},{"key":"10.1124\/pharmrev.120.000160_bib132","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.120.000160_bib133","series-title":"The Mechanism of Gated Calcium Transport Across Biological Membranes","year":"1981"},{"key":"10.1124\/pharmrev.120.000160_bib134","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2337\/db19-1145","article-title":"Excitotoxicity and overnutrition additively impair metabolic function and identity of pancreatic \u03b2-cells","volume":"69","author":"Osipovich","year":"2020","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib135","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1038\/s41598-018-26471-9","article-title":"Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes","volume":"8","author":"Osum","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.120.000160_bib136","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem J"},{"key":"10.1124\/pharmrev.120.000160_bib137","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00400631","article-title":"Intracellular localization and molecular heterogeneity of the sulphonylurea receptor in insulin-secreting cells","volume":"38","author":"Ozanne","year":"1995","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib138","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.1128294","article-title":"Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes","volume":"313","author":"Ozcan","year":"2006","journal-title":"Science"},{"key":"10.1124\/pharmrev.120.000160_bib139","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00007890-200202150-00007","article-title":"Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets","volume":"73","author":"Paty","year":"2002","journal-title":"Transplantation"},{"key":"10.1124\/pharmrev.120.000160_bib140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/dom.12450","article-title":"Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes","volume":"17","author":"Penesova","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib141","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","article-title":"Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome","volume":"7","author":"Perdigoto","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/pharmrev.120.000160_bib142","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","article-title":"Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects","volume":"46","author":"Perley","year":"1967","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib143","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/pharmrev.120.000160_bib144","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/dom.12826","article-title":"Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes","volume":"19","author":"Preiss","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib145","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib146","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1163\/156856293X00294","article-title":"In vitro activation of human macrophages by alginate-polylysine microcapsules","volume":"5","author":"Pueyo","year":"1993","journal-title":"J Biomater Sci Polym Ed"},{"key":"10.1124\/pharmrev.120.000160_bib147","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(01)39800-8","article-title":"Notes on suprarenal and pancreatic grafting","volume":"204","author":"Pybus","year":"1924","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.120.000160_bib148","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMoa2006136","article-title":"Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes","volume":"383","author":"Quattrin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib149","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4161\/cc.29250","article-title":"Dyrk1A induces pancreatic \u03b2 cell mass expansion and improves glucose tolerance","volume":"13","author":"Rachdi","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1124\/pharmrev.120.000160_bib150","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00125-014-3174-3","article-title":"Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass","volume":"57","author":"Rachdi","year":"2014","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib151","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MED.0000000000000345","article-title":"Development of glucose-responsive \u2018smart\u2019 insulin systems","volume":"24","author":"Rege","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1124\/pharmrev.120.000160_bib152","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib153","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/dc09-0374","article-title":"Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future","volume":"32","author":"Rewers","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib154","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1007\/s00125-016-4067-4","article-title":"Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes","volume":"59","author":"Richardson","year":"2016","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.120.000160_bib155","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.2337\/db12-1802","article-title":"Improvement in \u03b2-cell secretory capacity after human islet transplantation according to the c7 protocol","volume":"62","author":"Rickels","year":"2013","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib156","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1210\/er.2018-00154","article-title":"Pancreatic islet transplantation in humans: recent progress and future directions","volume":"40","author":"Rickels","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1124\/pharmrev.120.000160_bib157","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1369\/0022155415576543","article-title":"Heterogeneity and lobularity of pancreatic pathology in type 1 diabetes during the prediabetic phase","volume":"63","author":"Rodriguez-Calvo","year":"2015","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/pharmrev.120.000160_bib158","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"10.1124\/pharmrev.120.000160_bib159","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1128\/MCB.23.20.7222-7229.2003","article-title":"Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis","volume":"23","author":"Rosen","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1124\/pharmrev.120.000160_bib160","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2337\/diacare.27.6.1265","article-title":"Repaglinide versus nateglinide monotherapy: a randomized, multicenter study","volume":"27","author":"Rosenstock","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.120.000160_bib161","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2215\/CJN.06860810","article-title":"Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients","volume":"6","author":"Sampaio","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/pharmrev.120.000160_bib162","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.celrep.2019.07.009","article-title":"The GLP1R agonist liraglutide reduces hyperglucagonemia induced by the SGLT2 inhibitor dapagliflozin via somatostatin release","volume":"28","author":"Saponaro","year":"2019","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000160_bib163","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2337\/db19-0888","article-title":"Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets","volume":"69","author":"Saponaro","year":"2020","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib164","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1210\/endo.136.10.7545106","article-title":"Contribution of L- and non-L-type calcium channels to voltage-gated calcium current and glucose-dependent insulin secretion in HIT-T15 cells","volume":"136","author":"Satin","year":"1995","journal-title":"Endocrinology"},{"key":"10.1124\/pharmrev.120.000160_bib165","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/jc.2015-1215","article-title":"Effects of TZD use and discontinuation on fracture rates in ACCORD Bone Study","volume":"100","author":"Schwartz","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib166","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1210\/en.2002-220564","article-title":"Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway","volume":"143","author":"Shalev","year":"2002","journal-title":"Endocrinology"},{"key":"10.1124\/pharmrev.120.000160_bib167","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2337\/db17-1331","article-title":"Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes","volume":"67","author":"Shankar","year":"2018","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib168","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib169","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1172\/JCI79264","article-title":"Insulin demand regulates \u03b2 cell number via the unfolded protein response","volume":"125","author":"Sharma","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/MED.0000000000000548","article-title":"The role of beta-cell dysfunction in early type 1 diabetes","volume":"27","author":"Sims","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1124\/pharmrev.120.000160_bib171","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cell.2015.06.025","article-title":"Genetic variation determines PPAR\u03b3 function and anti-diabetic drug response in vivo","volume":"162","author":"Soccio","year":"2015","journal-title":"Cell"},{"key":"10.1124\/pharmrev.120.000160_bib172","doi-asserted-by":"crossref","first-page":"40050","DOI":"10.1074\/jbc.M110.154955","article-title":"Calcineurin signaling regulates human islet beta-cell survival","volume":"285","author":"Soleimanpour","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/pharmrev.120.000160_bib173","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3727\/096368911X603620","article-title":"Metabolic function of a suboptimal transplanted islet mass in nonhuman primates on rapamycin monotherapy","volume":"21","author":"Soleimanpour","year":"2012","journal-title":"Cell Transplant"},{"key":"10.1124\/pharmrev.120.000160_bib174","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.tem.2013.03.005","article-title":"The pancreatic \u03b2 cell and type 1 diabetes: innocent bystander or active participant?","volume":"24","author":"Soleimanpour","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib175","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib176","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.2337\/db16-1355","article-title":"Chronic \u03b2-cell depolarization impairs \u03b2-cell identity by disrupting a network of Ca2+-regulated genes","volume":"66","author":"Stancill","year":"2017","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib177","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2337\/db14-1843","article-title":"Human \u03b2-cell proliferation and intracellular signaling: part 3","volume":"64","author":"Stewart","year":"2015","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib178","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2174\/1381612823666170214120708","article-title":"Cell-based tolerogenic therapy, experience from animal models of multiple sclerosis, type 1 diabetes and rheumatoid arthritis","volume":"23","author":"Stojanovic","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1124\/pharmrev.120.000160_bib179","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1172\/JCI41280","article-title":"An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells","volume":"120","author":"Sturek","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2018.10.009","article-title":"SGLT1 in pancreatic \u03b1 cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels","volume":"19","author":"Suga","year":"2019","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.120.000160_bib181","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000160_bib182","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0039-6109(16)41489-1","article-title":"Pancreatic islet cell transplantation","volume":"58","author":"Sutherland","year":"1978","journal-title":"Surg Clin North Am"},{"key":"10.1124\/pharmrev.120.000160_bib183","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2337\/db11-1293","article-title":"Islet \u03b2-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model","volume":"61","author":"Tersey","year":"2012","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib184","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2020.07.002","article-title":"Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action","volume":"32","author":"Thielen","year":"2020","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.120.000160_bib185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.120.000160_bib186","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1124\/pharmrev.120.000160_bib187","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1472-8206.1987.tb00549.x","article-title":"Sensitivity of pancreatic beta cell to calcium channel blockers. An electrophysiologic study of verapamil and nifedipine","volume":"1","author":"Vasseur","year":"1987","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/pharmrev.120.000160_bib188","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nbt.3462","article-title":"Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates","volume":"34","author":"Vegas","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1124\/pharmrev.120.000160_bib189","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41467-018-08193-8","article-title":"Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion","volume":"10","author":"Vergari","year":"2019","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000160_bib190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12902-016-0097-7","article-title":"Cost effectiveness and value of information analyses of islet cell transplantation in the management of \u2018unstable\u2019 type 1 diabetes mellitus","volume":"16","author":"Wallner","year":"2016","journal-title":"BMC Endocr Disord"},{"key":"10.1124\/pharmrev.120.000160_bib191","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41467-017-00992-9","article-title":"Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.120.000160_bib192","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"key":"10.1124\/pharmrev.120.000160_bib193","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-1033.1983.tb07382.x","article-title":"Identification of the lipid-binding site of phosphatidylcholine-transfer protein with phosphatidylcholine analogs containing photoactivable carbene precursors","volume":"132","author":"Westerman","year":"1983","journal-title":"Eur J Biochem"},{"key":"10.1124\/pharmrev.120.000160_bib194","unstructured":"World Health Organization (2020) World Health Organization Diabetes Fact Sheet."},{"key":"10.1124\/pharmrev.120.000160_bib195","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1124\/pharmrev.120.000160_bib196","first-page":"1303","article-title":"Notes on diabetes treated with extract and by grafts of sheep\u2019s pancreas","volume":"2","author":"Williams","year":"1894","journal-title":"BMJ"},{"key":"10.1124\/pharmrev.120.000160_bib197","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/bmj.1.2100.760","article-title":"On the treatment of glycosuria and diabetes mellitus with sodium salicylate","volume":"1","author":"Williamson","year":"1901","journal-title":"BMJ"},{"key":"10.1124\/pharmrev.120.000160_bib198","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1172\/JCI14178","article-title":"The blooming of the French lilac","volume":"108","author":"Witters","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib199","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.120.000160_bib200","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.120.000160_bib201","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib202","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/db11-0955","article-title":"Preventing \u03b2-cell loss and diabetes with calcium channel blockers","volume":"61","author":"Xu","year":"2012","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib203","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/db19-0879","article-title":"Connecting rodent and human pharmacokinetic models for the design and translation of glucose-responsive insulin","volume":"69","author":"Yang","year":"2020","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.120.000160_bib204","doi-asserted-by":"crossref","first-page":"317.e11","DOI":"10.1016\/j.amjmed.2017.09.044","article-title":"Sulfonylureas as initial treatment for type 2 diabetes and the risk of severe hypoglycemia","volume":"131","author":"Yu","year":"2018","journal-title":"Am J Med"},{"key":"10.1124\/pharmrev.120.000160_bib205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.120.000160_bib206","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724006823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.120.000160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:20:32Z","timestamp":1739870432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724006823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":206,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0031699724006823"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.120.000160","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Aspects of Diabetes Research and Therapeutic Development","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.120.000160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 U.S. Government work not protected by U.S. copyright.","name":"copyright","label":"Copyright"}]}}